Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers

Table 3 Correlations between TILs and pCR in neoadjuvant treated TNBCs

Variables	Univariate analysis			Multivariate analysis
Variables	OR	95% CI	P-value	OR	95% CI	P-value
ITILs (per 10%)	1.10	1.04–1.16	0.001*	1.06	1.00-1.12	0.04*
STILs (per 10%)	1.07	1.03–1.10	0.0001*	1.05	1.02-1.09	0.006*
Age (years) (< 50 vs. ≥50)	0.51	0.27–0.95	0.04*	0.65	0.31-1.35	0.25
Histological grade (2 vs. 3)	2.74	1.11–6.80	0.03*	1.02	0.34-3.08	0.98
Tumor size (cm) (≤2 vs. 2–5 vs. > 5)	1.30	0.74–2.29	0.37	1.30	0.68–2.47	0.43
Nodal status (negative vs. positive)	0.93	0.48–1.81	0.84	1.52	0.72–3.22	0.28
LVI (negative vs. positive)	0.06	0.01–0.26	0.0001*	0.07	0.02-0.29	0.0001*
Ki-67 index	1.03	1.01–1.04	0.001*	1.02	1.006-1.04	0.009*
NAC (Anthracycline + paclitaxel vs. paclitaxel + platinum)	0.83	0.37–1.87	0.65	1.10	0.41–2.94	0.85

Abbreviations: pCR pathological complete response, TNBCs triple-negative breast cancers, sTILs stromal tumor-infiltrating lymphocytes, iTILs intratumoral tumor-infiltrating lymphocytes, LVI lymphovascular invasion, NAC neoadjuvant chemotherapy, OR odds ratio, 95% CI 95% confidence interval
*The P value is significant

ISSN: 1746-1596